Create and grow our dream in AMENIS BIOSCIENCE

In 2025, we aim to lead the development pipeline for pandemic antiviral drugs, MASH therapies, and anticancer drugs leveraging small molecule production technology. Through collaborative research with Japanese universities, we strive to make our diverse pipelines best-in-class.